

Investor News
No. 08/2011

Zealand Pharma to present at UBS Global Specialty Pharmaceuticals Conference 2011

Copenhagen, 23 May 2011 – Zealand Pharma (NASDAQ OMX: ZEAL), a biopharmaceutical company based in Denmark, announces that the company will present at the UBS Global Specialty Pharmaceuticals Conference 2011 in London on Wednesday, 25 May 2011. The presentation will be held by David H. Solomon, Chief Executive Officer and President, and is scheduled for 9:30 a.m. BST (10:30am CEST).

A copy of the slides will be available under Calendar/Other events in the investor section of the company's website; ir.zealandpharma.com prior to the presentation. No new material information will be disclosed.

For further information, please contact:

Hanne Leth Hillman, Vice President for IR & Corporate Communications
Mobile: +45 5060 3689

About Zealand Pharma

Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) biopharmaceutical company based in Copenhagen, Denmark with a mature and growing clinical pipeline of innovative peptide drugs. The company's lead product candidate is a once-daily GLP-1, which is completing Phase III development for the treatment of Type 2 Diabetes in collaboration with Sanofi. Zealand Pharma also has other collaboration and licensing partnerships, including a license agreement with Helsinn Healthcare on a clinical stage GLP-2 drug for the treatment of Chemotherapy and Radiotherapy Induced Diarrhea.

Zealand Pharma has unique expertise in peptide discovery and optimization and in the development of novel peptide drugs with favorable therapeutic attributes. The company's products target disease areas, where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of peptide drugs is high. All of Zealand Pharma's product candidates have been identified through the company's own drug discovery activities. For more information please visit www.zealandpharma.com.